In parallel with working towards discovering and advancing therapeutic psychedelics, biopharma companies are continuously protecting their findings. Theemerging biotech BetterLife Pharma Inc. BETRF has filed an international PCT along with a U.S. patent applicationfor the composition and use within the treatment of LSD derivatives for mental health conditions such as depression, PTSD, anxiety, cluster headaches and pain.<\/p>\n
One of BetterLifes main compounds under development, BETR-001, will be covered by these patent filings. The proprietary drug is a new composition of 2-bromo-LSD and a second-gen LSD derivative molecule that does not cause hallucinations and therefore is not subject to global controlled substance regulations.<\/p>\n
BETR-001s synthesis is done through non-controlled substance synthetic routes, which also makes it not subject to controlled substance regulatory restrictions and therefore plausible for self-administration.<\/p>\n
The company is at advanced stages of GMP-manufacturing and completion of preclinical IND-enabling studies for BETR-001, expecting to file the IND and begin Phase 1 clinical studiesin the first half of 2023.<\/p>\n
CEO Dr. Ahmad Doroudian explained that the inventions covered by the patent filings are comprehensive and involve a significant body of data including composition of matter, preclinical in-vitro and in-vivo characterization of BETR-001, which the company expects to soon submit for publication in a peer-reviewed journal.<\/p>\n
Considering the data generated to date, the company believes its proprietary drug holds great promise in becoming a major treatment for a range of mental health and neurological conditions, including depression, anxiety, pain and related disorders.<\/p>\n
Betterlifes other main drug development, BETR-002, is currently in preclinical and IND-enabling studies. This proprietary compound is based on honokiol, the active anxiolytic ingredient of magnolia bark, and its pending method of use and formulations patent covers the treatment of anxiety-related disorders, including benzodiazepine dependence.<\/p>\n
Photo courtesy ofOlia Danilevich onPexels.<\/p>\n
<\/p>\n
More:<\/p>\n
Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives - Bett - Benzinga<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" In parallel with working towards discovering and advancing therapeutic psychedelics, biopharma companies are continuously protecting their findings. Continue reading